ving the value growth of the Novo Nordisk ® iabetes value market 5% USD 55 billion 2021 Traditional OADs Diabetes market dynamics • Innovation focused on oral GLP-1 • Contin a u n ed d s c t o r m on b g in g a r t o i w on th s momentum in GLP-1 and SGLT-2i segments • Biosimilar competition and loss • DPP-4i o s f e e g x m c e lu n s t i t v o it h y ave first patent expiries on key products within the coming two years • Diabetes technology with digital • Flat ins h u e li a n lt v h olume growth and continued insulin pricing pressure • Patients’ outcome beyond glucose control • Evolving payer dynamics and market access hurdles • Access and affordability of medicine pound annual growth rates. OAD: Oral anti-diabetes P-1, SGLT-2i and DPP-4i and IQVIA data for traditional OADs as of December 2018 and 2021
Download PDF file